Longevity & AgingLow-Dose Naltrexone Shows Early Promise for Long COVID Function and Symptoms
Low-dose naltrexone was linked to improved symptoms and daily functioning in 230 adults with long COVID, according to research presented at IDWeek. Researchers reviewed clinic records and compared patients’ symptoms before treatment with follow-up visits while taking the drug. A seven-symptom score declined, patients reported fewer symptoms, and functional scores improved. These results matter because long COVID can limit exercise, work, and everyday activities. However, the study had no placebo or untreated comparison group, so it cannot show that naltrexone caused the improvements. Recovery over time, other treatments, and treatment expectations could also explain the changes. The supplied article cuts off before final dosing and safety details. Low-dose naltrexone remains an experimental, off-label option for long COVID that requires clinician guidance and confirmation in randomized trials.
